|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
| Drug Highest PhaseApproved | 
| First Approval Ctry. / Loc.United States | 
| First Approval Date04 Jun 2021 | 
| Target- | 
| MechanismImmunostimulants | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhaseApproved | 
| First Approval Ctry. / Loc.United States | 
| First Approval Date12 Nov 1998 | 
| Target- | 
| MechanismImmunostimulants | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhaseApproved | 
| First Approval Ctry. / Loc.United States | 
| First Approval Date12 Nov 1998 | 
100 Clinical Results associated with Emergent Biodefense Operations Lansing LLC
0  Patents (Medical) associated with Emergent Biodefense Operations Lansing LLC
100 Deals associated with Emergent Biodefense Operations Lansing LLC
100 Translational Medicine associated with Emergent Biodefense Operations Lansing LLC